ArticleRNA biology2014
CRISPR adaptive immune systems of Archaea.
Article in RNA biology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 78 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
78 citing papers in PubMed, 1 synthesis or guideline pooled it.
- CRISPR-cas gene-editing as plausible treatment of neuromuscular and nucleotide-repeat-expansion diseases: A systematic review.PloS one · 2019Pooled it
- Research Progress in Applications of the CRISPR-Cas12b System in Pathogen Nucleic Acid Detection.Current issues in molecular biology · 2026Review
- Comprehensive analysis of CRISPR array repeat mutations reveals subtype-specific patterns and links to spacer dynamics.microLife · 2026Article
- Internal in-frame translation generates Cas11b, which is important for effective interference in an archaeal CRISPR-Cas system.Frontiers in microbiology · 2025Article
- Impacts of Climate Change and Mitigation Strategies for Some Abiotic and Biotic Constraints Influencing Fruit Growth and Quality.Plants (Basel, Switzerland) · 2024Review
- Genome editing using CRISPR, CAST, and Fanzor systems.Molecules and cells · 2024Review
- Expanding known viral diversity in the healthy infant gut.Nature microbiology · 2023Article
- Novel ribotype/sequence type associations and diverse CRISPR-Cas systems in environmental Clostridioides difficile strains from northern Iraq.FEMS microbiology letters · 2023Article
- An outlook to sophisticated technologies and novel developments for metabolic regulation in theFrontiers in bioengineering and biotechnology · 2023Review
- Application of the endogenous CRISPR-Cas type I-D system for genetic engineering in the thermoacidophilic archaeonFrontiers in microbiology · 2023Article
- Biochemical characterization of the two novel mgCas12a proteins from the human gut metagenome.Scientific reports · 2022Article
- Conserved and lineage-specific hypothetical proteins may have played a central role in the rise and diversification of major archaeal groups.BMC biology · 2022Article
- Assessment of Biofortification Approaches Used to Improve Micronutrient-Dense Plants That Are a Sustainable Solution to Combat Hidden Hunger.Journal of soil science and plant nutrition · 2022Review
- Diversity of the type I-U CRISPR-Cas system in Bifidobacterium.Archives of microbiology · 2021Article
- CRISPRloci: comprehensive and accurate annotation of CRISPR-Cas systems.Nucleic acids research · 2021Article
- Casboundary: automated definition of integral Cas cassettes.Bioinformatics (Oxford, England) · 2021Article
- CRISPR-Cas adaptive immune systems in Sulfolobales: genetic studies and molecular mechanisms.Science China. Life sciences · 2021Review
- Characterization of 67 Confirmed Clustered Regularly Interspaced Short Palindromic Repeats Loci in 52 Strains ofFrontiers in microbiology · 2021Article
- Heavily Armed Ancestors: CRISPR Immunity and Applications in Archaea with a Comparative Analysis of CRISPR Types in Sulfolobales.Biomolecules · 2020Review
- DNA targeting by subtype I-D CRISPR-Cas shows type I and type III features.Nucleic acids research · 2020Article
18 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
CRISPR adaptive immune systems were analyzed for all available completed genomes of archaea, which included representatives of each of the main archaeal phyla. Initially, all proteins encoded within, and proximal to, CRISPR-cas loci were clustered and analyzed using a profile-profile approach. Then cas genes were assigned to gene cassettes and to functional modules for adaptation and interference. CRISPR systems were then classified primarily on the basis of their concatenated Cas protein sequences and gene synteny of the interference modules. With few exceptions, they could be assigned to the universal Type I or Type III systems. For Type I, subtypes I-A, I-B, and I-D dominate but the data support the division of subtype I-B into two subtypes, designated I-B and I-G. About 70% of the Type III systems fall into the universal subtypes III-A and III-B but the remainder, some of which are phyla-specific, diverge significantly in Cas protein sequences, and/or gene synteny, and they are classified separately. Furthermore, a few CRISPR systems that could not be assigned to Type I or Type III are categorized as variant systems. Criteria are presented for assigning newly sequenced archaeal CRISPR systems to the different subtypes. Several accessory proteins were identified that show a specific gene linkage, especially to Type III interference modules, and these may be cofunctional with the CRISPR systems. Evidence is presented for extensive exchange having occurred between adaptation and interference modules of different archaeal CRISPR systems, indicating the wide compatibility of the functionally diverse interference complexes with the relatively conserved adaptation modules.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.